Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Analysts at Jefferies Group issued their Q1 2017 earnings estimates for shares of Zynerba Pharmaceuticals in a research note issued on Monday. Jefferies Group analyst B. Amin forecasts that the firm will post earnings of ($0.62) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $32.00 price target on the stock. Jefferies Group also issued estimates for Zynerba Pharmaceuticals’ Q2 2017 earnings at ($0.58) EPS and Q3 2017 earnings at ($0.62) EPS.
ZYNE has been the topic of a number of other research reports. Roth Capital set a $25.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Zynerba Pharmaceuticals in a report on Friday, December 16th. Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Saturday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of Zynerba Pharmaceuticals in a report on Thursday, January 5th. Finally, Oppenheimer Holdings Inc. set a $29.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 18th. Nine research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $30.56.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.mideasttime.com/brokers-issue-forecasts-for-zynerba-pharmaceuticals-incs-q1-2017-earnings-zyne/1590016.html.
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) opened at 21.16 on Tuesday. Zynerba Pharmaceuticals has a 52 week low of $6.02 and a 52 week high of $23.75. The company’s 50 day moving average price is $20.76 and its 200-day moving average price is $15.99. The firm’s market capitalization is $210.61 million.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Monday, March 27th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.04. During the same period last year, the firm earned ($0.62) EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $214,000. Putnam Investments LLC purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $725,000. J. Goldman & Co LP purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $1,113,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $13,128,000. Institutional investors own 15.00% of the company’s stock.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp bought 10,000 shares of Zynerba Pharmaceuticals stock in a transaction on Thursday, December 29th. The shares were purchased at an average price of $15.85 per share, with a total value of $158,500.00. Following the acquisition, the insider now owns 1,354,115 shares in the company, valued at approximately $21,462,722.75. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.02% of the company’s stock.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.